ketanserin has been researched along with Cancer of Pancreas in 1 studies
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.
ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Leja-Szpak, A | 1 |
| Pierzchalski, P | 1 |
| Goralska, M | 1 |
| Nawrot-Porabka, K | 1 |
| Bonior, J | 1 |
| Link-Lenczowski, P | 1 |
| Jastrzebska, M | 1 |
| Jaworek, J | 1 |
1 other study available for ketanserin and Cancer of Pancreas
| Article | Year |
|---|---|
Kynuramines induce overexpression of heat shock proteins in pancreatic cancer cells via 5-hydroxytryptamine and MT1/MT2 receptors.
Topics: Cell Line, Tumor; Heat-Shock Proteins; Humans; Ketanserin; Kynuramine; Melatonin; Pancreatic Neoplas | 2015 |